Drug news
FDA accepts NDA filing for Nuplazid (pimavanserin) to treat Parkinsons disease psychosis- Acadia Pharma
The NDA for Nuplazid (pimavanserin) from Acadia Pharma has been accepted for review by the FDA and the agency has granted it Priority Review for the treatment of psychosis associated with Parkinson’s disease. The FDA has set a target action date under PDUFA of May 1, 2016.
Comment: Pimavanserin is Acadia's proprietary small molecule that acts selectively as an antagonist/inverse agonist on serotonin 5-HT2A receptors and is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. Pimavanserin can be taken once-daily as a tablet.